Alfi (ALFIW) Competitors

$0.0002
0.00 (0.00%)
(As of 05/15/2024 ET)

ALFIW vs. BTX, CIDM, and NLOK

Should you be buying Alfi stock or one of its competitors? The main competitors of Alfi include Brooklyn ImmunoTherapeutics (BTX), Cinedigm (CIDM), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.

Alfi vs.

Brooklyn ImmunoTherapeutics (NYSE:BTX) and Alfi (NASDAQ:ALFIW) are both information companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk.

In the previous week, Brooklyn ImmunoTherapeutics had 1 more articles in the media than Alfi. MarketBeat recorded 1 mentions for Brooklyn ImmunoTherapeutics and 0 mentions for Alfi. Alfi's average media sentiment score of 0.00 equaled Brooklyn ImmunoTherapeutics'average media sentiment score.

Company Overall Sentiment
Brooklyn ImmunoTherapeutics Neutral
Alfi Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brooklyn ImmunoTherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Alfi
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Brooklyn ImmunoTherapeutics and Alfi both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Brooklyn ImmunoTherapeuticsOutperform Votes
No Votes
Underperform Votes
72
100.00%
AlfiN/AN/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brooklyn ImmunoTherapeuticsN/AN/AN/A-$2.27-0.89
Alfi$200.68KN/AN/AN/AN/A

26.0% of Brooklyn ImmunoTherapeutics shares are owned by institutional investors. 20.5% of Brooklyn ImmunoTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Brooklyn ImmunoTherapeuticsN/A N/A N/A
Alfi N/A N/A N/A

Summary

Brooklyn ImmunoTherapeutics beats Alfi on 3 of the 4 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALFIW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALFIW vs. The Competition

MetricAlfiSoftware Publishers IndustryInformation SectorNASDAQ Exchange
Market CapN/AN/A$3.68B$7.95B
Dividend YieldN/AN/A3.69%3.93%
P/E RatioN/AN/A7.3518.78
Price / SalesN/AN/A3.9187.14
Price / CashN/AN/AN/A31.19
Price / BookN/AN/AN/A4.47
Net IncomeN/AN/AN/A$217.14M
7 Day PerformanceN/AN/A4.02%2.78%
1 Month PerformanceN/AN/A0.54%6.02%
1 Year PerformanceN/AN/A1.76%9.67%

Alfi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTX
Brooklyn ImmunoTherapeutics
0 of 5 stars
$2.35
+9.8%
N/A-29.8%$138.24MN/A-1.04N/AAnalyst Forecast
Gap Down
CIDM
Cinedigm
0 of 5 stars
$0.93
+10.7%
N/AN/A$173.46M$72.33M-18.56140Analyst Forecast
News Coverage
NLOK
NortonLifeLock
0 of 5 stars
$24.00
+2.3%
N/A+52.7%$13.71B$2.82B16.78N/A

Related Companies and Tools

This page (NASDAQ:ALFIW) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners